Cantor starts Organogenesis at overweight, cites differentiated portfolio

admin

Cantor starts Organogenesis at overweight, cites differentiated portfolio


Bet_Noire

Cantor Fitzgerald has initiated coverage of Organogenesis (NASDAQ:ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio.

Cantor said it holds a favorable view of the estimated $24B advanced wound care and surgical/sports medicine markets. It sees

SOURCE

Leave a Comment